Parcourir MS 2017 num. 11 par sujet "Pédiatrie"
Voici les éléments 1-1 de 1
(Éditions EDK, Groupe EDP Sciences, 2017)The first therapy based on chimeric antigen receptors has been approved by the FDA. It gives excellent results in recurrent paediatric ALL; its cost is very high but fairly consistent with the clinical benefit (long term ...